How to Isolate Bacteriophages from Environmental Samples

Phage host range determines which bacterial strains a phage can infect. Studies show that most isolated phages can infect a broad range of host strains, with only about 13.5% of samples failing to infect any tested host. This specificity is determined by the compatibility between phage receptors and bacterial surface structures. Understanding host range is crucial for selecting appropriate phages for therapeutic applications.

Host range determination—the identification of which bacterial species a phage can infect—is critical but problematic due to multiple competing methods lacking standardization. This research compared four techniques (spot testing with/without dilutions, plaque testing, culture lysis) using quantitative meta-analysis of 22 studies. While overall material usage showed no significant differences, spot testing without dilutions used significantly less phage filtrate than plaque testing, making it more resource-efficient for high-throughput screening needed in therapeutic development.

Phages are isolated by filtering environmental samples and growing bacteria on selective media. Phages are identified by creating plaques (clear zones where bacteria have been lysed). Phage specificity is determined by receptor binding - each phage can only attach to bacteria with specific surface proteins. This mechanism is analogous to how viruses bind to host cell receptors.

Different lambda phage strains have different tail fiber variants that determine their host range. The gpJ protein contains a receptor-binding domain that recognizes specific bacterial receptors. Some lambda phage strains have evolved modified tail fibers that recognize different receptors, allowing them to infect different bacterial strains. This evolution of host range is an important aspect of phage ecology and evolution.

Comprehensive phage characterization includes: Efficiency of Plating (EOP)—serial dilution to find highest dilution producing confluent lysis; Routine Test Dilution—the highest dilution failing to produce confluent lysis (standard for future testing); Single Step Growth Curve—analyzing sigmoid curves to determine latent period (time to maximum growth rate) and burst size (phages released per cell); Host Range Determination—testing coverage across bacterial species within genus or family; PFGE for genome sizing; Electron microscopy for morphological identification. Different phages show varying lytic activities: clear confluent lysis, opalescent lysis, no reaction, individual plaques, or resistant mutants. For difficult-to-culture bacteria like Bacteroides, metagenomic approaches are used: extract all genetic material from the sample, sequence it, and use bioinformatics to distinguish phage sequences from host and human DNA. The CRASS phage was discovered this way in human fecal metagenomes—it is 97 kb and six times more abundant than all other known phages combined. Temperate phages can integrate their DNA into bacterial genomes (lysogeny), avoiding lysis. To detect lysogenic phages: Mitomycin C induction—add 4-8 μg/ml to bacterial cultures, incubate 2 hours, then incubate overnight with shaking; UV irradiation—expose diluted bacterial cultures (OD 0.2-0.3) to 6-30 mJ/cm² UV-C, then incubate overnight. Both methods induce the lytic cycle, allowing detection of previously latent phages through plaque formation on host lawns.

Advanced bioinformatics tools enable comprehensive phage genome analysis: DNA Master predicts gene locations using probability algorithms; Famirator compares genomes to identify conserved gene clusters and evolutionary relationships; HHpred assigns protein functions and predicts 3D structures. Analysis of Goose phage revealed 87 genes, including a stolen bacterial endonuclease gene repurposed for host attack and an integrase gene lost due to dispensability. The tape measure protein determines tail length through precise molecular counting during assembly.

Phage genome organization is conserved within families (synteny). Cytovirid genomes have left arm encoding structural genes (terminase, portal, lysis cassette) and right arm encoding early lysogenic genes. Lysogenic cassette (attP, integrase, immunity repressor) is central. Protoid genomes have different organization with terminal protein at 5' end. Terminal proteins serve as primers for DNA replication, with serine hydroxyl group attaching first nucleotide. This conservation allows gene function prediction based on position—for example, genes following tape measure protein are likely minor tail proteins. Phage structural proteins include major capsid protein, portal protein, terminase, capsid maturation protease, scaffolding protein, and minor tail proteins. Understanding genome organization and packaging mechanisms is essential for genome annotation and comprehending phage biology.

Phage genomes contain genes organized in functional regions: structural genes (capsid, tail) at the beginning, and genes for host interaction (injection, lysis, lysogeny) at the end. The region containing immunity repressors and integrases determines whether the phage causes bacterial death (lytic cycle) or integrates into the host genome (lysogenic cycle). Isolated bacteriophages are deposited in public databases (such as the Actinobacteriophage Database) for global scientific access. Phages are also preserved in ultra-freezers at -80°C for long-term storage and potential clinical applications.

The lysogenic cycle is a temperate state where bacteriophage DNA integrates into the bacterial chromosome as a prophage, remaining dormant without producing new particles. This allows passive propagation through bacterial binary fission, exponentially increasing phage DNA copies. The prophage can remain integrated for many generations until environmental triggers induce phage conversion to the lytic cycle. This dual-cycle strategy provides evolutionary advantages: lysogeny ensures survival during unfavorable conditions while maintaining latent infectivity, while lytic phase enables explosive reproduction when conditions permit.

Bacteriophage therapy offers several advantages over antibiotics: they are easy to isolate from various sources including water, soil, and clinical samples; they are highly specific to target bacterial strains; they self-replicate in the presence of target bacteria, increasing concentration proportionally with bacterial load; and they can be used against multidrug-resistant infections when antibiotics fail. The FDA has approved phage therapy for compassionate use in patients with multidrug-resistant infections when no other treatment options exist. This has successfully treated septicemia, infected valve infections, and other life-threatening bacterial infections. The case of Stephanie Strachan, who survived a multidrug-resistant Citrobacter baumannii infection through phage therapy after conventional treatments failed, contributed to the formation of an institution dedicated to studying bacteriophages.

Phage therapy offers multiple advantages over antibiotics. Phages are self-amplifying—they multiply at infection sites, manufacturing themselves where needed and disappearing when the job is done. They can penetrate biofilms that antibiotics cannot, dissolving protective bacterial shields or replicating inside structures. Phages preserve the microbiome by targeting only specific bacteria, avoiding the indiscriminate killing that causes C. diff infections and yeast overgrowths. Phages and antibiotics work synergistically, with studies showing over 90% bacterial eradication when combined versus 77% improvement alone. CRISPR-enhanced phages can reprogram bacteria to become antibiotic-sensitive or self-destruct. However, treating multidrug-resistant infections requires personalized phage cocktails: isolate and identify exact bacterial strains, screen hundreds of phages from libraries, combine three to eight different phages, amplify each separately, purify, test for contaminants, and combine in specific ratios. Multiply this by hundreds of patients—impossible without digital systems. Cloud-based manufacturing execution systems enable real-time tracking of phage libraries, production history, stability data, and efficacy profiles. Temperature control is critical—some phages need refrigeration while others are stable at room temperature. IoT sensors monitor conditions and trigger alerts for failures. Electronic batch records replace paper-based GMP documentation. Approximately 90 clinical trials are ongoing worldwide, with the Belgian consortium showing 77.2% clinical improvement and 61.3% bacterial eradication. The NIH is running trials for cystic fibrosis patients.

Bacteriophages are viruses that specifically infect and kill bacteria, representing the most abundant living organisms on Earth. They have been used in Eastern European countries for decades but fell into disuse due to lack of rigorous clinical studies. Phage therapy offers targeted treatment with minimal disruption to the microbiome, as phages only affect their specific bacterial hosts. Applications include intravenous administration, aerosol delivery, local application to wounds, and intravesical instillation. Phage therapy shows synergistic effects with antibiotics, restoring susceptibility to some antibiotics. Susceptibility testing (phagotyping) is performed by sending bacterial isolates to specialized laboratories. Clinical experience at CHIREC hospital with 21 patients treated for MDR Gram-negative infections shows predominantly OXA-48-producing Enterobacteriaceae, Pseudomonas with porin mutations and efflux pumps, and VIM-producing organisms.

Phage resistance develops primarily through bacterial receptor mutations, with larger phage genomes having greater capacity to overcome resistance. The coevolutionary 'arms race' between phages and bacteria involves trade-offs between resistance costs and infectivity. Phage-antibiotic synergy occurs through multiple mechanisms: antibiotics cause bacterial filamentation increasing phage sensitivity, phages accelerate lysis and virion production, and phages degrade bacterial capsules facilitating antibiotic penetration into biofilms. This synergy can restore antibiotic sensitivity in resistant bacteria. Phage susceptibility testing uses the double agar overlay method, calculating efficiency of plating (EOP) as the ratio of plaque-forming units on test versus reference bacteria. An EOP of at least 0.1 is considered therapeutic. However, some antibiotics (like rifampicin affecting RNA polymerase) can antagonize phage replication, requiring careful synergy testing.

Successful phage therapy implementation requires coordinated efforts across clinical, laboratory, and regulatory domains. Physicians identify difficult-to-treat infections, microbiology labs characterize resistant organisms, and specialized phage centers conduct susceptibility screening. FDA oversight through IND applications enables compassionate use while ensuring safety. Two major bottlenecks exist: finding appropriate phages (some organisms require extensive environmental sampling) and producing clinical-grade phages meeting pharmaceutical standards. Recent clinical trials provide compelling evidence: aerosolized phage cocktails reduced Pseudomonas counts by 2 logs in cystic fibrosis patients; phage plus antibiotic achieved >80% microbiological success in resistant UTIs; combined intravenous/topical phage accelerated healing in diabetic foot osteomyelitis; and phage therapy outperformed antibiotics alone in complicated Staphylococcus sepsis. These studies establish proof-of-concept and frameworks for larger trials, positioning phage therapy at an inflection point for mainstream integration.